Masahiko Sumii

The Effect of Pembrolizumab Plus Platinum-based Chemotherapy on the Progression-free Survival of Non-small-cell Lung Cancer with a High PD-L1 Expression and Large Baseline Tumor Size

Y. Iwamoto, Shohei Mishima, K. Masuda, 2021, Haigan.

Pre-Existing Interstitial Lung Abnormalities Are Independent Risk Factors for Interstitial Lung Disease during Durvalumab Treatment after Chemoradiotherapy in Patients with Locally Advanced Non-Small-Cell Lung Cancer

Y. Nagata, Y. Iwamoto, N. Hattori, 2022, Cancers.